MIME-Version: 1.0 X-Document-Type: Workbook Content-Type: multipart/related; boundary="----=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer. ------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Workbook.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

This page should be opened with Microsoft Excel XP or newer.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet01.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Document and Entity Information (USD  $)	3 Months Ended
Mar. 31, 2011	Apr. 29, 2011	Jun. 30, 2010
Document and Entity Information [Abstract]
Entity Registrant Name	AMGEN INC
Entity Central Index Key	0000318154
Document Type	10-Q
Document Period End Date	Mar 31, 2011
Amendment Flag	false
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 50,355,022,164
Entity Common Stock, Shares Outstanding		929,730,507

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet02.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Document and Entity Information (Parenthetical)	Jun. 30, 2010
Document and Entity Information [Abstract]
Common stock held by directors and officers and any stockholders whose ownership exceeds five percent of the shares outstanding	1,085,011

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet03.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Statements of Income (Unaudited) (USD  $) In Millions, except Per Share data	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Revenues:
Product sales	$ 3,618	$ 3,528
Other revenues	88	64
Total revenues	3,706	3,592
Operating expenses:
Cost of sales (excludes amortization of certain acquired intangible assets presented below)	564	508
Research and development	736	646
Selling, general and administrative	1,023	884
Amortization of certain acquired intangible assets	74	74
Other	16	(1)
Total operating expenses	2,413	2,111
Operating income	1,293	1,481
Interest expense, net	135	145
Interest and other income, net	148	84
Income before income taxes	1,306	1,420
Provisions for income taxes	181	253
Net income	$ 1,125	$ 1,167
Earnings per share:
Basic	$ 1.21	$ 1.19
Diluted	$ 1.2	$ 1.18
Shares used in calculation of earnings per share:
Basic	933	982
Diluted	941	988

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet04.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Balance Sheets (Unaudited) (USD  $) In Millions	3 Months Ended	12 Months Ended
Mar. 31, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 1,266	$ 3,287
Marketable securities	14,092	14,135
Trade receivables, net	2,517	2,335
Inventories	2,098	2,022
Other current assets	1,716	1,350
Total current assets	21,689	23,129
Property, plant and equipment, net	5,455	5,522
Intangible assets, net	2,808	2,230
Goodwill	11,504	11,334
Other assets	1,258	1,271
Total assets	42,714	43,486
Current liabilities:
Accounts payable	832	716
Accrued liabilities	3,334	3,366
Current portion of convertible notes	83	2,488
Total current liabilities	4,249	6,570
Convertible notes	2,246	2,296
Other long-term debt	8,578	8,578
Other non-current liabilities	2,657	2,098
Contingencies and commitments
Stockholders' equity:
Common stock and additional paid-in capital;  $0.0001 par value; 2,750 shares authorized; outstanding - 933 shares in 2011 and 932 shares in 2010	27,376	27,299
Accumulated deficit	(2,383)	(3,508)
Accumulated other comprehensive (loss) income	(9)	153
Total stockholders' equity	24,984	23,944
Total liabilities and stockholders' equity	$ 42,714	$ 43,486

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet05.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD  $) In Millions, except Per Share data	Mar. 31, 2011	Dec. 31, 2010
Stockholders' equity:
Common stock and additional paid-in capital, par value	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized	2,750	2,750
Common stock and additional paid-in capital, shares outstanding	933	932

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet06.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD  $) In Millions	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Cash flows from operating activities:
Net income	$ 1,125	$ 1,167
Depreciation and amortization	273	252
Stock-based compensation expense	77	68
Other items, net	14	10
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	(181)	(162)
Inventories	(78)	21
Other current assets	(62)	(43)
Accounts payable	(38)	308
Accrued income taxes	8	(189)
Other accrued liabilities	(108)	(519)
Net cash provided by operating activities	1,030	913
Cash flows from investing activities:
Purchases of property, plant and equipment	(100)	(94)
Cash paid for acquisitions, net of cash acquired	(403)	0
Purchases of marketable securities	(7,203)	(3,160)
Proceeds from sales of marketable securities	6,933	2,170
Proceeds from maturities of marketable securities	224	141
Other	(6)	(12)
Net cash used in investing activities	(555)	(955)
Cash flows from financing activities:
Repayment of debt	(2,500)	0
Repurchases of common stock	(14)	(1,587)
Net proceeds from issuance of debt	0	989
Net proceeds from issuance of common stock in connection with the Company's equity award programs	16	26
Other	2	(4)
Net cash used in financing activities	(2,496)	(576)
Decrease in cash and cash equivalents	(2,021)	(618)
Cash and cash equivalents at beginning of period	3,287	2,884
Cash and cash equivalents at end of period	$ 1,266	$ 2,266

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet07.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary of significant accounting policies	3 Months Ended
Mar. 31, 2011
Summary of significant accounting policies [Abstract]
Summary of significant accounting policies	1. Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. We concentrate on innovating novel medicines based on advances in cellular and molecular biology and we operate in one business segment, human therapeutics. Basis of presentation The financial information for the three months ended March 31, 2011 and 2010 is unaudited but includes all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2010. Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its wholly owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Revenue recognition for arrangements with multiple-deliverables From time to time, we enter into arrangements for the research and development (R&D), manufacture and/or commercialization of products and product candidates. These arrangements may require us to deliver various rights, services and/or goods across the entire life cycle of a product or product candidate, including (i) intellectual property rights/license, (ii) R&D services, (iii) manufacturing services and/or (iv) commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of non-refundable upfront license payments, R&D and commercial performance milestone payments, cost sharing and/or royalty payments. In October 2009, the Financial Accounting Standards Board issued a new accounting standard which amends the guidance on the accounting for arrangements involving the delivery of more than one element. This standard addresses the determination of the unit(s) of accounting for multiple-element arrangements and how the arrangement’s consideration should be allocated to each unit of accounting. The Company adopted this new accounting standard on a prospective basis for all multiple-element arrangements entered into on or after January 1, 2011 and for any multiple-element arrangements that were entered into prior to January 1, 2011 but materially modified on or after January 1, 2011. Pursuant to the new standard, each required deliverable is evaluated to determine if it qualifies as a separate unit of accounting. For Amgen this determination is generally based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price, and (iii) best estimate of selling price (BESP). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. We expect, in general, to use the BESP for allocating consideration to each deliverable. In general, the consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered limited to the consideration that is not contingent upon future deliverables. For multiple-element arrangements entered into prior to January 1, 2011 and not materially modified thereafter, we continue to apply our prior accounting policy with respect to such arrangements. Under this policy, in general, revenue from non-refundable, upfront fees related to intellectual property rights/licenses where we have continuing involvement is recognized ratably over the estimated period of ongoing involvement because there is no objective and reliable evidence of fair value for any undelivered item to allow the delivered item to be considered a separate unit of accounting. This requirement with respect to the fair value of undelivered items was eliminated in the newly issued accounting standard. In general, the consideration with respect to the other deliverables is recognized when the goods or services are delivered. Under all of our multiple-element arrangements, consideration associated with at risk substantive performance milestones is recognized as revenue upon the achievement of the related milestone, as defined in the respective agreements. The impact of adopting this new accounting standard is dependent on the terms and conditions of any future arrangement that we may enter into that includes multiple-deliverables, however, its adoption is not expected to have a material impact on our consolidated results of operations or financial position. The primary impact of adopting the new accounting standard is expected to be the earlier recognition of revenue associated with delivering rights to the underlying intellectual property. The adoption of this accounting standard did not have a material impact on our condensed consolidated results of operations or financial position for the three months ended March 31, 2011. Our consolidated results of operations or financial position for 2010 also would not have been materially impacted if the accounting standard had been adopted on January 1, 2010. Inventories Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner which approximates the first-in, first-out method. Cost also includes the impact of the recently enacted Puerto Rico excise tax related to our manufacturing operations in Puerto Rico. The Company capitalizes inventories produced in preparation for product launches when the related product candidates are considered to have a high probability of regulatory approval and the related costs are expected to be recoverable through the commercialization of the product. See Note 7, Inventories. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of  $5.3 billion and  $5.2 billion as of March 31, 2011 and December 31, 2010, respectively. Business combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our condensed consolidated financial statements. The excess of the acquisition date fair value of consideration over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination are recorded at their fair values on the acquisition date. We revalue these obligations each subsequent reporting period until the related contingencies are resolved and record changes in their fair values in earnings. See Note 2, Acquisitions.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet08.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions	3 Months Ended
Mar. 31, 2011
Acquisitions [Abstract]
Acquisitions	2.   Acquisitions On March 4, 2011, we acquired all of the outstanding stock of BioVex Group, Inc. (BioVex), a privately held biotechnology company developing treatments for cancer and the prevention of infectious disease, including OncoVEXGM-CSF, a novel oncolytic vaccine in phase 3 clinical development for the treatment of melanoma and head and neck cancer. This transaction, which was accounted for as a business combination, provides us with an opportunity to expand our efforts to bring novel therapeutics to market. Upon its acquisition, BioVex became a wholly owned subsidiary of Amgen. The aggregate acquisition date consideration to acquire BioVex consisted of (in millions):         Cash paid to former shareholders of BioVex    $ 407 Fair value of contingent consideration obligations     190       Total consideration    $ 597       The cash consideration reflects a reduction in the purchase price related to changes in working capital and excludes amounts that have been and may be paid to the employees of BioVex who became Amgen employees upon the acquisition, including  $7 million paid to settle unvested employee options to acquire stock in BioVex which we expensed at the acquisition date. In connection with this acquisition, we are obligated to make additional payments to the former shareholders of BioVex of up to  $575 million contingent upon the achievement of certain regulatory and sales milestones with regard to OncoVEXGM-CSF, including the filing of a biologics license application with the U.S. Food and Drug Administration (FDA), the first commercial sale in each of the United States and the European Union following receipt of marketing approval, which includes use of the product in specified patient populations, and upon achieving specified levels of sales. The estimated aggregate fair value of the contingent consideration obligations as of the acquisition date of  $190 million was determined using a combination of valuation techniques. The contingent consideration obligations to make regulatory milestone payments were valued based on assumptions regarding the probability of achieving the milestones and making the related payments with such amounts discounted to present value. The contingent consideration obligations to make sales milestone payments were valued based on assumptions regarding the probability of achieving specified product sales thresholds to determine the required payments with such amounts discounted to present value. We allocated the total consideration to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):         Intangible assets — IPR&D    $ 675 Goodwill     170 Deferred tax liabilities     (246 ) Other assets and liabilities acquired, net     (2 )       Total consideration    $ 597       Intangible assets are composed of the estimated fair value of acquired IPR&D related to OncoVEXGM-CSF. The estimated fair value was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The estimated net cash flows were discounted to present value using a discount rate of 11%, which is based on the estimated weighted average cost of capital for companies with characteristics similar to BioVex. This is comparable to the estimated internal rate of return on BioVex operations and represents the rate that market participants would use to value the intangible assets. The projected cash flows from OncoVEXGM-CSF were based on certain key assumptions, including estimates of future revenue and expenses taking into account the stage of development of OncoVEXGM-CSF at the acquisition date, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. IPR&D intangible assets acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of  $170 million was recorded as goodwill, which is not deductible for tax purposes. Goodwill is primarily attributable to the deferred tax consequences of acquired IPR&D recorded for financial statement purposes. The amounts initially recorded for acquired IPR&D intangible assets and tax-related liabilities are preliminary. The amounts will be finalized upon collection of the appropriate information with respect to the BioVex intercompany arrangements related to the acquired IPR&D and the tax impacts thereof. BioVex is included in our condensed consolidated financial statements commencing on the acquisition date. Pro forma supplemental condensed consolidated financial information assuming the acquisition occurred on January 1, 2011 and 2010 is not provided as the impact would not be material to our condensed consolidated results of operations.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet09.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income taxes	3 Months Ended
Mar. 31, 2011
Income taxes [Abstract]
Income taxes	3. Income taxes The effective tax rates for the three months ended March 31, 2011 and 2010 are different from the statutory rates primarily as a result of indefinitely invested earnings of our foreign operations. We do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be invested indefinitely outside the United States. The effective tax rate for the three months ended March 31, 2011 was further reduced by foreign tax credits associated with the new Puerto Rico excise tax. Commencing January 1, 2011, Puerto Rico imposes a temporary excise tax on the purchase of goods and services from a related manufacturer in Puerto Rico. This excise tax is currently scheduled to expire in 2016. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, a significant portion of the excise tax results in tax credits that are recognized in our provision for income taxes when the excise tax is paid. Our effective tax rate for the three months ended March 31, 2011 without the impact of the tax credits associated with the new Puerto Rico excise tax would have been 18.8%. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely audited by the tax authorities in those jurisdictions. Significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income among various tax jurisdictions because of differing interpretations of tax laws and regulations. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2006 or to California state income tax examinations for years ended on or before December 31, 2003. The Internal Revenue Service (IRS) is currently examining our U.S. income tax returns for the years ended December 31, 2007, 2008 and 2009. As of March 31, 2011, the Company and the IRS have agreed to certain transfer pricing adjustments for the year ended December 31, 2009 and the Company has, accordingly, adjusted its liability for unrecognized tax benefits (UTBs) as discussed below. The remainder of this examination is expected to be completed in 2012. During the three months ended March 31, 2011, the gross amount of our UTBs increased by approximately  $72 million as a result of tax positions taken during the current year. During the three months ended March 31, 2011, the gross amount of our UTBs decreased by approximately  $201 million as a result of resolving certain transfer pricing matters related to prior years. Substantially all of the UTBs as of March 31, 2011, if recognized, would affect our effective tax rate.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet10.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings per share	3 Months Ended
Mar. 31, 2011
Earnings per share [Abstract]
Earnings per share	4. Earnings per share The computation of basic earnings per share (EPS) is based upon the weighted-average number of our common shares outstanding. The computation of diluted EPS is based upon the weighted-average number of our common shares and dilutive potential common shares outstanding. Dilutive potential common shares outstanding, determined using the treasury stock method, principally include: shares that may be issued under our stock option, restricted stock and performance unit awards; our 2011 Convertible Notes and 2013 Convertible Notes, as discussed below; and our outstanding warrants (collectively “dilutive securities”). The convertible note hedges purchased in connection with the issuance of our convertible notes are excluded from the calculation of diluted EPS as their impact is always anti-dilutive. Upon conversion of our 2011 Convertible Notes (while they were outstanding) and 2013 Convertible Notes, the principal amount would be settled in cash and the excess of the conversion value, as defined, over the principal amount may be settled in cash and/or shares of our common stock. Therefore, only the shares of our common stock potentially issuable with respect to the excess of the notes’ conversion value over their principal amount, if any, are considered as dilutive potential common shares for purposes of calculating diluted EPS. The following table sets forth the computation for basic and diluted EPS (in millions, except per share data):                     Three months ended     March 31,     2011     2010 Income (Numerator):               Net income for basic and diluted EPS    $ 1,125      $ 1,167                             Shares (Denominator):               Weighted-average shares for basic EPS     933       982 Effect of dilutive securities     8       6             Weighted-average shares for diluted EPS     941       988                             Basic EPS    $ 1.21      $ 1.19 Diluted EPS    $ 1.20      $ 1.18 For the three months ended March 31, 2011 and 2010, there were employee stock options, calculated on a weighted average basis, to purchase 39 million and 40 million shares of our common stock, respectively, with exercise prices greater than the average market prices of our common stock for these periods that are not included in the computation of diluted EPS as their impact would have been anti-dilutive. In addition, shares of our common stock which may be issued upon exercise of our warrants are not included in the computation of diluted EPS for any of the periods presented above as their impact would have been anti-dilutive.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet11.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Cost savings initiatives	3 Months Ended
Mar. 31, 2011
Cost savings initiatives [Abstract]
Cost savings initiatives	5. Cost savings initiatives Manufacturing operations at Fremont, California As part of continuing efforts to optimize our network of manufacturing facilities and improve cost efficiencies, on January 18, 2011, we entered into an agreement whereby Boehringer Ingelheim (BI) agreed to acquire all of our rights in and substantially all assets at our manufacturing operations located in Fremont, California. The transaction was approved by Amgen’s Board of Directors in December 2010 and closed in March 2011. In connection with the closing of this transaction, BI has or will assume our obligations under the facility’s operating lease agreements and has entered into an agreement to manufacture certain quantities of our marketed product Vectibix®, for us at this facility through December 31, 2012 (the “supply agreement”). Due to the lack of sufficient initial investment by BI in the acquisition of this facility and our ongoing involvement with these operations, the transaction did not meet the accounting requirements to be treated as a sale involving real estate. As a result, the related assets will continue to be carried on our Condensed Consolidated Balance Sheet. We considered this transaction with BI to be a potential indicator of impairment and, accordingly, we performed an impairment analysis of the carrying values of the related fixed assets as of December 31, 2010. Based on this analysis, we determined that no future economic benefit would be received from a manufacturing line at the facility that had not yet been completed. As a result, we wrote off its entire carrying value, which aggregated  $118 million for the three months ended December 31, 2010. The carrying values of the remaining fixed assets, aggregating approximately  $133 million, were determined to be fully recoverable. However, as a result of this transaction, we reduced the estimated remaining useful lives of these fixed assets to coincide with the period covered by the supply agreement. During the three months ended March 31, 2011, we recorded incremental depreciation in excess of what otherwise would have been recorded of approximately  $10 million. This amount is included in Cost of sales (excludes amortization of certain acquired intangible assets presented below) in the Condensed Consolidated Statement of Income. In addition, due to the assignment to BI of the obligations under certain of the facility’s operating leases in March 2011, we recorded a charge of approximately  $11 million in the three months ended March 31, 2011 with respect to the lease period beyond the end of the supply agreement. This amount is recorded in Cost of sales (excludes amortization of certain acquired intangible assets presented below) in the Condensed Consolidated Statement of Income. Other As part of continuing efforts to improve cost efficiencies in our manufacturing operations, we also recorded certain charges aggregating  $16 million during the three months ended March 31, 2011, which are included in Other in the Condensed Consolidated Statement of Income.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet12.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-for-sale investments	3 Months Ended
Mar. 31, 2011
Available-for-sale investments [Abstract]
Available-for-sale investments	6. Available-for-sale investments The fair values of available-for-sale investments by type of security, contractual maturity and classification in the Condensed Consolidated Balance Sheets were as follows (in millions):                                             Gross     Gross     Estimated     Amortized     unrealized     unrealized     fair Type of security as of March 31, 2011   cost     gains     losses     value U.S. Treasury securities    $ 3,573      $ 7      $ (23 )    $ 3,557 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     1,660       13       (2 )     1,671 Foreign and other     796       14       —       810 Corporate debt securities:                               Financial     2,957       55       (11 )     3,001 Industrial     3,131       72       (6 )     3,197 Other     352       10       (1 )     361 Mortgage and asset backed securities     1,498       4       (7 )     1,495 Money market mutual funds     1,075       —       —       1,075                         Total debt securities     15,042       175       (50 )     15,167 Equity securities     52       —       (4 )     48                              $ 15,094      $ 175      $ (54 )    $ 15,215                                                                     Gross     Gross     Estimated     Amortized     unrealized     unrealized     fair Type of security as of December 31, 2010   cost     gains     losses     value U.S. Treasury securities    $ 5,044      $ 50      $ (14 )    $ 5,080 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     2,158       51       (1 )     2,208 Foreign and other     837       16       (1 )     852 Corporate debt securities:                               Financial     2,252       53       (9 )     2,296 Industrial     2,441       71       (5 )     2,507 Other     307       10       (1 )     316 Mortgage and asset backed securities     841       5       (5 )     841 Money market mutual funds     3,030       —       —       3,030 Other short-term interest bearing securities     147       —       —       147                         Total debt securities     17,057       256       (36 )     17,277 Equity securities     50       —       (2 )     48                              $ 17,107      $ 256      $ (38 )    $ 17,325                                                March 31,        December 31, Contractual maturity   2011     2010 Maturing in one year or less    $ 1,713      $ 4,118 Maturing after one year through three years     7,049       6,736 Maturing after three years through five years     5,367       5,812 Maturing after five years     1,038       611             Total debt securities     15,167       17,277 Equity securities     48       48                  $ 15,215      $ 17,325                                    March 31,        December 31, Classification in the Condensed Consolidated Balance Sheets   2011     2010 Cash and cash equivalents    $ 1,266      $ 3,287 Marketable securities     14,092       14,135 Other assets — noncurrent     48       48                   15,406       17,470 Less cash     (191 )     (145 )                  $ 15,215      $ 17,325             For the three months ended March 31, 2011 and 2010, realized gains totaled  $89 million and  $21 million, respectively, and realized losses totaled  $8 million and  $2 million, respectively. The cost of securities sold is based on the specific identification method. The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits debt security investments to certain types of debt and money market instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and extent to which the fair value has been below our cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security by a rating agency. As of March 31, 2011 and December 31, 2010, we believe the cost bases for our available-for-sale investments were recoverable in all material respects.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet13.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories	3 Months Ended
Mar. 31, 2011
Inventories [Abstract]
Inventories	7. Inventories Inventories consisted of the following (in millions):                        March 31,        December 31,     2011     2010 Raw materials    $ 135      $ 128 Work in process     1,445       1,382 Finished goods     518       512                  $ 2,098      $ 2,022

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet14.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financing arrangements	3 Months Ended
Mar. 31, 2011
Financing arrangements [Abstract]
Financing arrangements	8. Financing arrangements The following table reflects the carrying values and the fixed contractual coupon rates of our borrowings under our various financing arrangements (dollar amounts in millions):                        March 31,        December 31,     2011     2010 0.125% convertible notes due 2011 (2011 Convertible Notes)    $ —      $ 2,488 0.375% convertible notes due 2013 (2013 Convertible Notes)     2,246       2,213 5.85% notes due 2017 (2017 Notes)     1,099       1,099 4.85% notes due 2014 (2014 Notes)     1,000       1,000 5.70% notes due 2019 (2019 Notes)     998       998 6.40% notes due 2039 (2039 Notes)     996       996 6.375% notes due 2037 (2037 Notes)     899       899 3.45% notes due October 2020 (October 2020 Notes)     897       897 5.75% notes due 2040 (2040 Notes)     696       696 4.95% notes due 2041 (2041 Notes)     595       595 6.15% notes due 2018 (2018 Notes)     499       499 6.90% notes due 2038 (2038 Notes)     499       499 4.50% notes due March 2020 (March 2020 Notes)     300       300 Other notes including our zero coupon convertible notes     183       183             Total borrowings     10,907       13,362 Less current portion     (83 )     (2,488 )             Total non-current debt    $ 10,824      $ 10,874             The holders of our zero coupon convertible notes due in 2032 have the right to put the debt to us for repayment on March 1, 2012. Accordingly the debt is classified as a current liability as of March 31, 2011. Debt repayments In February 2011, the 2011 Convertible Notes became due, and we repaid the  $2.5 billion aggregate principal amount. As these convertible notes were cash settleable, the debt and equity components of these notes were bifurcated and accounted for separately. The discounted carrying value of the debt component resulting from the bifurcation was accreted back to the principal amount over the period the notes were outstanding. The total aggregate amount repaid, including the amount related to the debt discount of  $643 million resulting from the bifurcation, is included in Cash flows from financing activities in the Condensed Consolidated Statements of Cash Flows. Shelf registration statement In March 2011, we filed a shelf registration statement with the Securities and Exchange Commission (SEC) to replace an existing shelf registration statement that was scheduled to expire in April 2011. This shelf registration allows us to issue an unspecified amount of: debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration expires in March 2014.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet15.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' equity	3 Months Ended
Mar. 31, 2011
Stockholders' equity [Abstract]
Stockholders' equity	9. Stockholders’ equity Stock repurchase program The following table is a summary of activity under our stock repurchase program (in millions):                                     2011     2010     Shares     Dollars     Shares     Dollars First quarter     —      $ —       29.1      $ 1,684                         In December 2009, the Board of Directors authorized us to repurchase up to an additional  $5.0 billion of our common stock of which a total of  $2.2 billion remains available as of March 31, 2011. In addition, in April 2011, the Board of Directors authorized us to repurchase up to an additional  $5.0 billion of our common stock.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet16.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair value measurement	3 Months Ended
Mar. 31, 2011
Fair value measurement [Abstract]
Fair value measurement	10. Fair value measurement We use various valuation approaches in determining the fair value of our financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:           Level 1   —   Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access           Level 2   —   Valuations for which all significant inputs are observable, either directly or indirectly, other than level 1 inputs           Level 3   —   Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The following fair value hierarchy tables present information about each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in millions):                                     Quoted prices in     Significant     Significant           active markets for       other observable             unobservable             Fair value measurement   identical assets     inputs     inputs       as of March 31, 2011 using:   (Level 1)     (Level 2)     (Level 3)                  Total              Assets:                               Available-for-sale securities:                               U.S. Treasury securities    $ 3,557      $ —      $ —      $ 3,557 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     —       1,671       —       1,671 Foreign and other     —       810       —       810 Corporate debt securities:                               Financial     —       3,001       —       3,001 Industrial     —       3,197       —       3,197 Other     —       361       —       361 Mortgage and asset backed securities     —       1,495       —       1,495 Money market mutual funds     1,075       —       —       1,075 Equity securities     48       —       —       48 Derivatives:                               Foreign currency contracts     —       57       —       57 Interest rate swap contracts     —       160       —       160                         Total assets    $ 4,680      $ 10,752      $ —      $ 15,432                                                         Liabilities:                               Derivatives:                               Foreign currency contracts    $ —      $ 189      $ —      $ 189 Interest rate swap contracts     —       12       —       12 Contingent consideration obligations in connection with a business combination     —       —       190       190                         Total liabilities    $ —      $ 201      $ 190      $ 391                                                             Quoted prices in     Significant     Significant           active markets for       other observable             unobservable             Fair value measurement   identical assets     inputs     inputs       as of December 31, 2010 using:   (Level 1)     (Level 2)     (Level 3)                  Total              Assets:                               Available-for-sale securities:                               U.S. Treasury securities    $ 5,080      $ —      $ —      $ 5,080 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     —       2,208       —       2,208 Foreign and other     —       852       —       852 Corporate debt securities:                               Financial     —       2,296       —       2,296 Industrial     —       2,507       —       2,507 Other     —       316       —       316 Mortgage and asset backed securities     —       841       —       841 Money market mutual funds     3,030       —       —       3,030 Other short-term interest bearing securities     —       147       —       147 Equity securities     48       —       —       48 Derivatives:                               Foreign currency contracts     —       154       —       154 Interest rate swap contracts     —       195       —       195                         Total assets    $ 8,158      $ 9,516      $ —      $ 17,674                                                         Liabilities:                               Derivatives:                               Foreign currency contracts    $ —      $ 103      $ —      $ 103                         Total liabilities    $ —      $ 103      $ —      $ 103                         The fair value of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets with no valuation adjustment. Substantially all of our other government related and corporate debt securities are investment grade with maturity dates of five years or less. Our other government related debt securities portfolio is comprised of securities with a weighted average credit rating of “AAA” or equivalent by Standard and Poor’s (S&P), Moody’s Investors Services, Inc. (Moody’s) or Fitch, Inc. (Fitch), and our corporate debt securities portfolio has a weighted average credit rating of “A” or equivalent by S&P, Moody’s or Fitch. We estimate the fair value of these securities taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker/dealer quotes of the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. Our mortgage and asset backed securities portfolio is comprised entirely of senior tranches, with a credit rating of “AAA” or equivalent by S&P, Moody’s or Fitch. We estimate the fair value of these securities taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker/dealer quotes of the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. We value our other short-term interest bearing securities at amortized cost which approximates fair value given their near term maturity dates. Substantially all of our foreign currency forward and option derivatives contracts have maturities of three years or less and all are entered into with counterparties that have a minimum credit rating of “A-” or equivalent by S&P, Moody’s or Fitch. We estimate the fair value of these contracts taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include quoted foreign currency spot rates, forward points, London Interbank Offered Rate (LIBOR) and swap curves and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts also include implied volatility measures. These inputs, where applicable, are at commonly quoted intervals. As of March 31, 2011 and December 31, 2010, we had open foreign currency forward contracts with notional amounts of  $3.4 billion and  $3.2 billion, respectively, and open foreign currency option contracts with notional amounts of  $300 million and  $398 million, respectively, that were primarily Euro-based and were designated as cash flow hedges. In addition, as of March 31, 2011 and December 31, 2010, we had  $788 million and  $670 million, respectively, of open foreign currency forward contracts to reduce exposure to fluctuations in value of certain assets and liabilities denominated in foreign currencies that were primarily Euro-based and that were not designated as hedges. (See Note 11, Derivative instruments.) Our interest rate swap contracts are entered into with counterparties that have a minimum credit rating of “A-” or equivalent by S&P, Moody’s or Fitch. We estimate the fair value of these contracts using an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR and swap curves and obligor credit default swap rates. We had interest rate swap agreements with an aggregate notional amount of  $3.6 billion as of March 31, 2011 and December 31, 2010 that were designated as fair value hedges. (See Note 11, Derivative instruments.) Contingent consideration obligations in connection with a business combination were incurred as a result of our acquisition of BioVex in March 2011. The fair value measurements of contingent consideration obligations are based on significant unobservable inputs, and accordingly, such amounts are considered Level 3 measurements. There was no material change in the fair values of these obligations from the acquisition date through March 31, 2011. For a description of the valuation methodology and related assumptions used to estimate the fair values of the contingent consideration obligations, see Note 2, Acquisitions. There have been no transfers of assets or liabilities between the fair value measurement levels and there were no material remeasurements to fair value during the three months ended March 31, 2011 and 2010 of assets and liabilities that are not measured at fair value on a recurring basis. Summary of the fair value of other financial instruments Short-term assets and liabilities The estimated fair values of cash equivalents, accounts receivable and accounts payable approximate their carrying values due to the short-term nature of these financial instruments. Borrowings We estimate the fair value of our convertible notes using an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly, including benchmark yields adjusted for our credit risk (Level 2). The fair values of our convertible notes exclude their equity components and represent only the liability components of these instruments as their equity components are included in Common stock and additional paid-in capital in the Condensed Consolidated Balance Sheets. We estimate the fair value of our other long-term notes taking into consideration indicative prices obtained from a third party financial institution that utilizes industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly. These inputs include reported trades and broker/dealer quotes of the same or similar securities, credit spreads, benchmark yields and other observable inputs (Level 2). The following tables present the carrying values and estimated fair values of our borrowings (in millions):                                     March 31, 2011     December 31, 2010     Carrying value        Fair value        Carrying value        Fair value    2011 Convertible Notes    $ —      $ —      $ 2,488      $ 2,501 2013 Convertible Notes     2,246       2,480       2,213       2,479 2017 Notes     1,099       1,245       1,099       1,280 2014 Notes     1,000       1,094       1,000       1,101 2019 Notes     998       1,107       998       1,139 2039 Notes     996       1,089       996       1,149 2037 Notes     899       974       899       1,027 October 2020 Notes     897       836       897       857 2040 Notes     696       699       696       734 2041 Notes     595       546       595       564 2018 Notes     499       568       499       584 2038 Notes     499       591       499       607 March 2020 Notes     300       307       300       311 Other notes including our zero coupon debt     183       204       183       214                         Total    $ 10,907      $ 11,740      $ 13,362      $ 14,547

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet17.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative instruments	3 Months Ended
Mar. 31, 2011
Derivative instruments [Abstract]
Derivative instruments	11. Derivative instruments The Company is exposed to risks related to its business operations, certain of which are managed through derivative instruments. The risks that we manage by using derivative instruments are foreign exchange rate risk and interest rate risk. We use financial instruments including foreign currency forward, foreign currency option, forward interest rate and interest rate swap contracts to reduce our risk to these exposures. We do not use derivatives for speculative trading purposes. We recognize all of our derivative instruments as either assets or liabilities at fair value in the Condensed Consolidated Balance Sheets (see Note 10, Fair value measurement). The accounting for changes in the fair value of a derivative instrument depends on whether it has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. Cash flow hedges We are exposed to possible changes in values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, associated primarily with our international product sales denominated in Euros. Increases or decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by the corresponding increases and decreases in our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations on our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon with, at any given point in time, a higher percentage of nearer term projected product sales being hedged than successive periods. As of March 31, 2011 and December 31, 2010, we had open foreign currency forward contracts with notional amounts of  $3.4 billion and  $3.2 billion, respectively, and open foreign currency option contracts with notional amounts of  $300 million and  $398 million, respectively. These foreign currency forward and option contracts, primarily Euro-based, have been designated as cash flow hedges, and accordingly, the effective portion of the unrealized gains and losses on these contracts are reported in Accumulated Other Comprehensive Income (AOCI) in the Condensed Consolidated Balance Sheets and reclassified to earnings in the same periods during which the hedged transactions affect earnings. In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on such contracts, which are designated as cash flow hedges, are reported in AOCI and amortized into earnings over the lives of the associated debt issuances. The following table reflects the effective portion of the unrealized gain/(loss) recognized in Other Comprehensive Income for our cash flow hedge contracts (in millions):                                     Three months ended             March 31, Derivatives in cash flow hedging relationships     2011     2010 Foreign currency contracts            $ (197 )    $ 175 Forward interest rate contracts             —       —                     Total            $ (197 )    $ 175                     The following table reflects the location in the Condensed Consolidated Statements of Income and the effective portion of the loss reclassified from AOCI into earnings for our cash flow hedge contracts (in millions):                                     Three months ended             March 31, Derivatives in cash flow hedging relationships   Statements of Income location     2011     2010 Foreign currency contracts   Product sales    $ (8 )    $ (6 ) Forward interest rate contracts   Interest expense, net     —       —                     Total            $ (8 )    $ (6 )                     No portions of our cash flow hedge contracts are excluded from the assessment of hedge effectiveness and the ineffective portions of these hedging instruments were approximately  $1 million of expense and approximately  $1 million of income for the three months ended March 31, 2011 and 2010, respectively. As of March 31, 2011, the amounts expected to be reclassified from AOCI into earnings over the next 12 months are approximately  $104 million of losses on foreign currency forward and option contracts and approximately  $1 million of losses on forward interest rate contracts. Fair value hedges To achieve a desired mix of fixed and floating interest rate debt, we have entered into interest rate swap agreements, which qualify and have been designated as fair value hedges. The terms of these interest rate swap agreements correspond to the related hedged debt instruments and effectively convert a fixed interest rate coupon to a floating LIBOR-based coupon over the lives of the respective notes. The rates on these swaps range from LIBOR plus 0.3% to LIBOR plus 2.6%. We had interest rate swap agreements with aggregate notional amounts of  $3.6 billion as of March 31, 2011 and December 31, 2010. The interest rate swap agreements as of March 31, 2011 and December 31, 2010 were for our notes due in 2014, 2017, 2018 and 2019. For derivative instruments that are designated and qualify as a fair value hedge, the unrealized gain or loss on the derivative resulting from the change in fair value during the period as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk are recognized in current earnings. For the three months ended March 31, 2011 and 2010, we included the unrealized gain on the hedged debt of  $47 million and the unrealized loss on the hedged debt of  $17 million, respectively, in the same line item, Interest expense, net in the Condensed Consolidated Statements of Income, as the offsetting unrealized loss of  $47 million and the unrealized gain of  $17 million, respectively, on the related interest rate swap agreements. Derivatives not designated as hedges We enter into foreign currency forward contracts to reduce our exposure to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies which are not designated as hedging transactions. These exposures are hedged on a month-to-month basis. As of March 31, 2011 and December 31, 2010, the total notional amounts of these foreign currency forward contracts, primarily Euro-based, were  $788 million and  $670 million, respectively. The following table reflects the location in the Condensed Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for the derivative instruments not designated as hedging instruments (in millions):                                     Three months ended             March 31, Derivatives not designated as hedging instruments   Statements of Income location     2011     2010 Foreign currency contracts   Interest and other income, net    $ (51 )    $ 23                     The following tables reflect the fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in the Condensed Consolidated Balance Sheets as of March 31, 2011 and December 31, 2010 (in millions):                                     Derivative assets     Derivative liabilities March 31, 2011   Balance Sheet location     Fair value     Balance Sheet location     Fair value Derivatives designated as hedging instruments:                               Interest rate swap contracts   Other current assets/Other non-current assets    $ 160     Accrued liabilities/Other non-current liabilities    $ 12                                 Foreign currency contracts   Other current assets/Other non-current assets     57     Accrued liabilities/Other non-current liabilities     189                                 Total derivatives designated as hedging instruments             217               201                                                             Derivatives not designated as hedging instruments:                               Foreign currency contracts   Other current assets     —     Accrued liabilities     —                                                             Total derivatives not designated as hedging instruments             —               —                             Total derivatives            $ 217            $ 201                                                               Derivative assets     Derivative liabilities December 31, 2010   Balance Sheet location     Fair value     Balance Sheet location     Fair value Derivatives designated as hedging instruments:                                                               Interest rate swap contracts   Other current assets/Other non-current assets    $ 195     Accrued liabilities/Other non-current liabilities    $ —                                 Foreign currency contracts   Other current assets/Other non-current assets     154     Accrued liabilities/Other non-current liabilities     103                                                             Total derivatives designated as hedging instruments             349               103                             Derivatives not designated as hedging instruments:                                                               Foreign currency contracts   Other current assets     —     Accrued liabilities     —                                                             Total derivatives not designated as hedging instruments             —               —                             Total derivatives            $ 349              $ 103                             Our derivative contracts that were in a liability position as of March 31, 2011 contain certain credit risk related contingent provisions that are triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. The cash flow effects of our derivatives contracts are included within Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet18.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Contingencies and commitments	3 Months Ended
Mar. 31, 2011
Contingencies and commitments [Abstract]
Contingencies and commitments	12. Contingencies and commitments In the ordinary course of business, we are involved in various legal proceedings and other matters, including those discussed in this Note, which are complex in nature and have outcomes that are difficult to predict. We record accruals for such contingencies to the extent that we conclude that it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. While it is not possible to accurately predict or determine the eventual outcome of these items, one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain of our legal proceedings and other matters are discussed below: Roche U.S. International Trade Commission Complaint On March 11, 2011, the U.S. International Trade Commission issued an order to show cause why the investigation should not be terminated without a determination of violation or by way of consent order in view of the resolution of the U.S. District Court for the District of Massachusetts proceedings. In response, on April 21, 2011, the parties filed a joint response requesting termination of the investigation on the basis of a proposed Consent Order and Stipulation. Teva Matters Sensipar® Abbreviated New Drug Application Litigation On April 19, 2011, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Barr Laboratories, Inc. filed an unopposed motion for voluntary dismissal of their appeal. On April 20, 2011, the U.S. Court of Appeals for the Federal Circuit granted the motion and dismissed the appeal. Simonian v. Amgen Inc. On April 12, 2011, Amgen and Mr. Simonian reached a settlement and the U.S. District Court for the Northern District of Illinois dismissed the case with prejudice. Average Wholesale Price Litigation Plaintiffs continue to file for extensions for the final approval hearing of the Track II settlement due to continued deficiencies in executing notices, and the final approval hearing is currently scheduled for June 13, 2011. Birch v. Sharer, et al. On February 24, 2011, plaintiff filed a notice of appeal with the California State Appellate Court. The schedule for briefing the appeal has not yet been set. Third-Party Payers Litigation No appeal was filed with the U.S. Supreme Court by the plaintiffs and the deadline for doing so has passed. Qui Tam Actions On April 26, 2011, the Massachusetts District Court changed the trial date to be set for the running trial list starting on October 3, 2011. On February 11, 2011, the states of New York, Massachusetts, California, Illinois and Indiana, on behalf of the states of Georgia and New Mexico, and the relator filed reply briefs and oral argument was heard by the U.S. Court of Appeals for the First Circuit on April 6, 2011. On April 11, 2011, the U.S. District Court for the District of Massachusetts heard summary judgment arguments on the fourth amended complaint from Amgen, Integrated Nephrology Network and the relator. Other In March 2011, the U.S. Attorney’s Office of the Western District of Washington informed Amgen that the subject matter of its investigation would be transferred to the U.S. Attorney’s Office of the Eastern District of New York.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet19.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Subsequent events	3 Months Ended
Mar. 31, 2011
Subsequent events [Abstract]
Subsequent events	13. Subsequent events In April 2011, we announced our acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda (Bergamo), a privately-held Brazilian pharmaceutical company, for approximately  $215 million in cash. Bergamo is a leading supplier of medicines to the hospital sector in Brazil with capabilities in oncology medicines. The company has approximately 400 staff, a portfolio of marketed products and manufacturing facilities in the state of Sao Paulo, Brazil. Upon its acquisition, Bergamo became a wholly owned subsidiary of Amgen. This acquisition will provide us with direct access to the Brazilian pharmaceutical market. This transaction will be accounted for as a business combination and included in our condensed consolidated financial statements commencing on the acquisition date. Pro forma supplemental condensed consolidated financial information for Amgen including the results of Bergamo assuming an acquisition date of January 1, 2011 and 2010 is not provided as the impact to our condensed consolidated results of operations would not be material, either individually or when aggregated with the acquisition of BioVex (see Note 2, Acquisitions).

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet20.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary of significant accounting policies (Policies)	3 Months Ended
Mar. 31, 2011
Summary of significant accounting policies (Policies) [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. We concentrate on innovating novel medicines based on advances in cellular and molecular biology and we operate in one business segment, human therapeutics.
Basis of presentation	Basis of presentation The financial information for the three months ended March 31, 2011 and 2010 is unaudited but includes all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2010.
Principles of consolidation	Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its wholly owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Revenue recognition for arrangements with multiple - deliverables	Revenue recognition for arrangements with multiple-deliverables From time to time, we enter into arrangements for the research and development (R&D), manufacture and/or commercialization of products and product candidates. These arrangements may require us to deliver various rights, services and/or goods across the entire life cycle of a product or product candidate, including (i) intellectual property rights/license, (ii) R&D services, (iii) manufacturing services and/or (iv) commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of non-refundable upfront license payments, R&D and commercial performance milestone payments, cost sharing and/or royalty payments. In October 2009, the Financial Accounting Standards Board issued a new accounting standard which amends the guidance on the accounting for arrangements involving the delivery of more than one element. This standard addresses the determination of the unit(s) of accounting for multiple-element arrangements and how the arrangement’s consideration should be allocated to each unit of accounting. The Company adopted this new accounting standard on a prospective basis for all multiple-element arrangements entered into on or after January 1, 2011 and for any multiple-element arrangements that were entered into prior to January 1, 2011 but materially modified on or after January 1, 2011. Pursuant to the new standard, each required deliverable is evaluated to determine if it qualifies as a separate unit of accounting. For Amgen this determination is generally based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price, and (iii) best estimate of selling price (BESP). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. We expect, in general, to use the BESP for allocating consideration to each deliverable. In general, the consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered limited to the consideration that is not contingent upon future deliverables. For multiple-element arrangements entered into prior to January 1, 2011 and not materially modified thereafter, we continue to apply our prior accounting policy with respect to such arrangements. Under this policy, in general, revenue from non-refundable, upfront fees related to intellectual property rights/licenses where we have continuing involvement is recognized ratably over the estimated period of ongoing involvement because there is no objective and reliable evidence of fair value for any undelivered item to allow the delivered item to be considered a separate unit of accounting. This requirement with respect to the fair value of undelivered items was eliminated in the newly issued accounting standard. In general, the consideration with respect to the other deliverables is recognized when the goods or services are delivered. Under all of our multiple-element arrangements, consideration associated with at risk substantive performance milestones is recognized as revenue upon the achievement of the related milestone, as defined in the respective agreements. The impact of adopting this new accounting standard is dependent on the terms and conditions of any future arrangement that we may enter into that includes multiple-deliverables, however, its adoption is not expected to have a material impact on our consolidated results of operations or financial position. The primary impact of adopting the new accounting standard is expected to be the earlier recognition of revenue associated with delivering rights to the underlying intellectual property. The adoption of this accounting standard did not have a material impact on our condensed consolidated results of operations or financial position for the three months ended March 31, 2011. Our consolidated results of operations or financial position for 2010 also would not have been materially impacted if the accounting standard had been adopted on January 1, 2010.
Inventories	Inventories Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner which approximates the first-in, first-out method. Cost also includes the impact of the recently enacted Puerto Rico excise tax related to our manufacturing operations in Puerto Rico. The Company capitalizes inventories produced in preparation for product launches when the related product candidates are considered to have a high probability of regulatory approval and the related costs are expected to be recoverable through the commercialization of the product. See Note 7, Inventories.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of  $5.3 billion and  $5.2 billion as of March 31, 2011 and December 31, 2010, respectively.
Business Combinations	Business combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our condensed consolidated financial statements. The excess of the acquisition date fair value of consideration over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination are recorded at their fair values on the acquisition date. We revalue these obligations each subsequent reporting period until the related contingencies are resolved and record changes in their fair values in earnings. See Note 2, Acquisitions.

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet21.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Tables) (BioVex Group Inc [Member])	3 Months Ended
Mar. 31, 2011
Business Acquisition [Line Items]
Aggregate acquisition date consideration to acquire an entity	Cash paid to former shareholders of BioVex    $ 407 Fair value of contingent consideration obligations     190       Total consideration    $ 597
Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed	Intangible assets — IPR&D    $ 675 Goodwill     170 Deferred tax liabilities     (246 ) Other assets and liabilities acquired, net     (2 )       Total consideration    $ 597

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet22.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings per share (Tables)	3 Months Ended
Mar. 31, 2011
Earnings per share (Tables) [Abstract]
Computation for basic and diluted EPS	Three months ended     March 31,     2011     2010 Income (Numerator):               Net income for basic and diluted EPS    $ 1,125      $ 1,167                             Shares (Denominator):               Weighted-average shares for basic EPS     933       982 Effect of dilutive securities     8       6             Weighted-average shares for diluted EPS     941       988                             Basic EPS    $ 1.21      $ 1.19 Diluted EPS    $ 1.20      $ 1.18

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet23.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-for-sale investments (Tables)	3 Months Ended
Mar. 31, 2011
Available-for-sale investments (Tables) [Abstract]
Fair values of available-for-sale investments by type of security	Gross     Gross     Estimated     Amortized     unrealized     unrealized     fair Type of security as of March 31, 2011   cost     gains     losses     value U.S. Treasury securities    $ 3,573      $ 7      $ (23 )    $ 3,557 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     1,660       13       (2 )     1,671 Foreign and other     796       14       —       810 Corporate debt securities:                               Financial     2,957       55       (11 )     3,001 Industrial     3,131       72       (6 )     3,197 Other     352       10       (1 )     361 Mortgage and asset backed securities     1,498       4       (7 )     1,495 Money market mutual funds     1,075       —       —       1,075                         Total debt securities     15,042       175       (50 )     15,167 Equity securities     52       —       (4 )     48                              $ 15,094      $ 175      $ (54 )    $ 15,215                                                                     Gross     Gross     Estimated     Amortized     unrealized     unrealized     fair Type of security as of December 31, 2010   cost     gains     losses     value U.S. Treasury securities    $ 5,044      $ 50      $ (14 )    $ 5,080 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     2,158       51       (1 )     2,208 Foreign and other     837       16       (1 )     852 Corporate debt securities:                               Financial     2,252       53       (9 )     2,296 Industrial     2,441       71       (5 )     2,507 Other     307       10       (1 )     316 Mortgage and asset backed securities     841       5       (5 )     841 Money market mutual funds     3,030       —       —       3,030 Other short-term interest bearing securities     147       —       —       147                         Total debt securities     17,057       256       (36 )     17,277 Equity securities     50       —       (2 )     48                              $ 17,107      $ 256      $ (38 )    $ 17,325
Fair values of available-for-sale investments by contractual maturity	March 31,        December 31, Contractual maturity   2011     2010 Maturing in one year or less    $ 1,713      $ 4,118 Maturing after one year through three years     7,049       6,736 Maturing after three years through five years     5,367       5,812 Maturing after five years     1,038       611             Total debt securities     15,167       17,277 Equity securities     48       48                  $ 15,215      $ 17,325
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	March 31,        December 31, Classification in the Condensed Consolidated Balance Sheets   2011     2010 Cash and cash equivalents    $ 1,266      $ 3,287 Marketable securities     14,092       14,135 Other assets — noncurrent     48       48                   15,406       17,470 Less cash     (191 )     (145 )                  $ 15,215      $ 17,325

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet24.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Tables)	3 Months Ended
Mar. 31, 2011
Inventories (Tables) [Abstract]
Inventories	March 31,        December 31,     2011     2010 Raw materials    $ 135      $ 128 Work in process     1,445       1,382 Finished goods     518       512                  $ 2,098      $ 2,022

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet25.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financing arrangements (Tables)	3 Months Ended
Mar. 31, 2011
Financing arrangements (Tables) [Abstract]
Carrying values and the fixed contractual coupon rates of borrowing under various financing arrangements	March 31,        December 31,     2011     2010 0.125% convertible notes due 2011 (2011 Convertible Notes)    $ —      $ 2,488 0.375% convertible notes due 2013 (2013 Convertible Notes)     2,246       2,213 5.85% notes due 2017 (2017 Notes)     1,099       1,099 4.85% notes due 2014 (2014 Notes)     1,000       1,000 5.70% notes due 2019 (2019 Notes)     998       998 6.40% notes due 2039 (2039 Notes)     996       996 6.375% notes due 2037 (2037 Notes)     899       899 3.45% notes due October 2020 (October 2020 Notes)     897       897 5.75% notes due 2040 (2040 Notes)     696       696 4.95% notes due 2041 (2041 Notes)     595       595 6.15% notes due 2018 (2018 Notes)     499       499 6.90% notes due 2038 (2038 Notes)     499       499 4.50% notes due March 2020 (March 2020 Notes)     300       300 Other notes including our zero coupon convertible notes     183       183             Total borrowings     10,907       13,362 Less current portion     (83 )     (2,488 )             Total non-current debt    $ 10,824      $ 10,874

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet26.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' equity (Tables)	3 Months Ended
Mar. 31, 2011
Stockholder's Equity (Tables) [Abstract]
Summary of activity under a stock repurchase program	2011     2010     Shares     Dollars     Shares     Dollars First quarter     —      $ —       29.1      $ 1,684

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet27.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair value measurement (Tables)	3 Months Ended
Mar. 31, 2011
Fair value measurement (Tables) [Abstract]
Information about each major class of the companys' financial assets and liabilities measured at fair value on a recurring basis	Quoted prices in     Significant     Significant           active markets for       other observable             unobservable             Fair value measurement   identical assets     inputs     inputs       as of March 31, 2011 using:   (Level 1)     (Level 2)     (Level 3)                  Total              Assets:                               Available-for-sale securities:                               U.S. Treasury securities    $ 3,557      $ —      $ —      $ 3,557 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     —       1,671       —       1,671 Foreign and other     —       810       —       810 Corporate debt securities:                               Financial     —       3,001       —       3,001 Industrial     —       3,197       —       3,197 Other     —       361       —       361 Mortgage and asset backed securities     —       1,495       —       1,495 Money market mutual funds     1,075       —       —       1,075 Equity securities     48       —       —       48 Derivatives:                               Foreign currency contracts     —       57       —       57 Interest rate swap contracts     —       160       —       160                         Total assets    $ 4,680      $ 10,752      $ —      $ 15,432                                                         Liabilities:                               Derivatives:                               Foreign currency contracts    $ —      $ 189      $ —      $ 189 Interest rate swap contracts     —       12       —       12 Contingent consideration obligations in connection with a business combination     —       —       190       190                         Total liabilities    $ —      $ 201      $ 190      $ 391                                                             Quoted prices in     Significant     Significant           active markets for       other observable             unobservable             Fair value measurement   identical assets     inputs     inputs       as of December 31, 2010 using:   (Level 1)     (Level 2)     (Level 3)                  Total              Assets:                               Available-for-sale securities:                               U.S. Treasury securities    $ 5,080      $ —      $ —      $ 5,080 Other government related debt securities:                               Obligations of U.S. government agencies and FDIC guaranteed bank debt     —       2,208       —       2,208 Foreign and other     —       852       —       852 Corporate debt securities:                               Financial     —       2,296       —       2,296 Industrial     —       2,507       —       2,507 Other     —       316       —       316 Mortgage and asset backed securities     —       841       —       841 Money market mutual funds     3,030       —       —       3,030 Other short-term interest bearing securities     —       147       —       147 Equity securities     48       —       —       48 Derivatives:                               Foreign currency contracts     —       154       —       154 Interest rate swap contracts     —       195       —       195                         Total assets    $ 8,158      $ 9,516      $ —      $ 17,674                                                         Liabilities:                               Derivatives:                               Foreign currency contracts    $ —      $ 103      $ —      $ 103                         Total liabilities    $ —      $ 103      $ —      $ 103
Carrying values and estimated fair values of borrowings	March 31, 2011     December 31, 2010     Carrying value        Fair value        Carrying value        Fair value    2011 Convertible Notes    $ —      $ —      $ 2,488      $ 2,501 2013 Convertible Notes     2,246       2,480       2,213       2,479 2017 Notes     1,099       1,245       1,099       1,280 2014 Notes     1,000       1,094       1,000       1,101 2019 Notes     998       1,107       998       1,139 2039 Notes     996       1,089       996       1,149 2037 Notes     899       974       899       1,027 October 2020 Notes     897       836       897       857 2040 Notes     696       699       696       734 2041 Notes     595       546       595       564 2018 Notes     499       568       499       584 2038 Notes     499       591       499       607 March 2020 Notes     300       307       300       311 Other notes including our zero coupon debt     183       204       183       214                         Total    $ 10,907      $ 11,740      $ 13,362      $ 14,547

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet28.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative instruments (Tables)	3 Months Ended
Mar. 31, 2011
Derivative instruments (Tables) [Abstract]
Effective portion of the unrealized gain/(loss) recognized in Other Comprehensive Income for our cash flow hedge contracts	Three months ended             March 31, Derivatives in cash flow hedging relationships     2011     2010 Foreign currency contracts            $ (197 )    $ 175 Forward interest rate contracts             —       —                     Total            $ (197 )    $ 175
Location in the Consolidated Statements of Income and the effective portion of the gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our cash flow hedge contracts	Three months ended             March 31, Derivatives in cash flow hedging relationships   Statements of Income location     2011     2010 Foreign currency contracts   Product sales    $ (8 )    $ (6 ) Forward interest rate contracts   Interest expense, net     —       —                     Total            $ (8 )    $ (6 )
Location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for the derivative instruments not designated as hedging instruments	Three months ended             March 31, Derivatives not designated as hedging instruments   Statements of Income location     2011     2010 Foreign currency contracts   Interest and other income, net    $ (51 )    $ 23
Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Consolidated Balance Sheets	Derivative assets     Derivative liabilities March 31, 2011   Balance Sheet location     Fair value     Balance Sheet location     Fair value Derivatives designated as hedging instruments:                               Interest rate swap contracts   Other current assets/Other non-current assets    $ 160     Accrued liabilities/Other non-current liabilities    $ 12                                 Foreign currency contracts   Other current assets/Other non-current assets     57     Accrued liabilities/Other non-current liabilities     189                                 Total derivatives designated as hedging instruments             217               201                                                             Derivatives not designated as hedging instruments:                               Foreign currency contracts   Other current assets     —     Accrued liabilities     —                                                             Total derivatives not designated as hedging instruments             —               —                             Total derivatives            $ 217            $ 201                                                               Derivative assets     Derivative liabilities December 31, 2010   Balance Sheet location     Fair value     Balance Sheet location     Fair value Derivatives designated as hedging instruments:                                                               Interest rate swap contracts   Other current assets/Other non-current assets    $ 195     Accrued liabilities/Other non-current liabilities    $ —                                 Foreign currency contracts   Other current assets/Other non-current assets     154     Accrued liabilities/Other non-current liabilities     103                                                             Total derivatives designated as hedging instruments             349               103                             Derivatives not designated as hedging instruments:                                                               Foreign currency contracts   Other current assets     —     Accrued liabilities     —                                                             Total derivatives not designated as hedging instruments             —               —                             Total derivatives            $ 349              $ 103

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet29.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary of significant accounting policies (Details) (USD  $) In Billions	Mar. 31, 2011	Dec. 31, 2010
Summary of significant accounting policies (Textuals) [Abstract]
Accumulated depreciation and amortization on property, plant and equipment	$ 5.3	$ 5.2

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet30.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Details) (BioVex Group Inc [Member], USD  $) In Millions	Mar. 04, 2011
Aggregate acquisition date consideration to acquire an entity
Cash paid to former shareholders of acquired entity	$ 407
Fair value of contingent consideration obligations	190
Total consideration	$ 597

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet31.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Details 1) (BioVex Group Inc [Member], USD  $) In Millions	Mar. 04, 2011
Allocation of total consideration to the acquisition date fair values of assets acquired and liabilities assumed
Intangible assets - in process research and development	$ 675
Goodwill	170
Deferred tax liabilities	(246)
Other assets and liabilities acquired, net	(2)
Total consideration	$ 597

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet32.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Details Textuals) (BioVex Group Inc [Member], USD  $) In Millions, unless otherwise specified	Mar. 04, 2011
Acquisitions (Textuals) [Abstract]
Payments to employees of acquired entity to settle unvested employee options	$ 7
Contingent consideration obligations	575
Estimated aggregate fair value of the contingent consideration obligations	190
Discount rate used to estimate fair value of acquired in process research and development	11.00%
Goodwill on acquisition	$ 170

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet33.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income taxes (Details) (USD  $) In Millions, unless otherwise specified	3 Months Ended
Mar. 31, 2011
Income taxes (Textuals) [Abstract]
Effective tax rate for the period excluding the impact of the tax credits associated with the new Puerto Rico excise tax	18.80%
Increase in gross amount of unrecognized tax benefits for period	$ 72
Decrease in gross amount of unrecognized tax benefits for period	$ 201

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet34.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings per share (Details) (USD  $) In Millions, except Per Share data	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Income (Numerator):
Net income for basic and diluted Earnings Per Share	$ 1,125	$ 1,167
Shares (Denominator):
Weighted-average shares for basic Earnings Per Share	933	982
Effect of dilutive securities	8	6
Weighted-average shares for diluted Earnings Per Share	941	988
Basic Earnings Per Share	$ 1.21	$ 1.19
Diluted Earnings Per Share	$ 1.2	$ 1.18

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet35.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Earnings per share (Details Textuals) In Millions	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Earnings per share (Textuals) [Abstract]
Antidilutive securities excluded from computation of diluted earnings per share, amount	39	40

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet36.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Cost savings initiatives (Details) (Optimization of Manufacturing Network [Member], USD  $) In Millions	3 Months Ended	12 Months Ended	3 Months Ended
Mar. 31, 2011 Other charges [Member]	Dec. 31, 2010 Other charges [Member] Asset Impairment Charges [Member]	Mar. 31, 2011	Dec. 31, 2010
Cost savings initiatives (Textuals) [Abstract]
Impairment of fixed assets		$ 118
Carrying value of remaining assets				133
Incremental depreciation included in cost of sales			10
Charge related to lease period beyond period of supply agreement			11
Other charges related to cost efficiencies	$ 16

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet37.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-for-sale investments (Details) (USD  $) In Millions	3 Months Ended	12 Months Ended
Mar. 31, 2011	Dec. 31, 2010
Fair values of available-for-sale investments by type of security
Amortized cost	$ 15,094	$ 17,107
Gross unrealized gains	175	256
Gross unrealized losses	(54)	(38)
Estimated fair value	15,215	17,325
US Treasury securities [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	3,573	5,044
Gross unrealized gains	7	50
Gross unrealized losses	(23)	(14)
Estimated fair value	3,557	5,080
Other government related debt securities - Obligations of U.S. government agencies and FDIC guaranteed bank debt [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	1,660	2,158
Gross unrealized gains	13	51
Gross unrealized losses	(2)	(1)
Estimated fair value	1,671	2,208
Other government related debt securities - Foreign and other [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	796	837
Gross unrealized gains	14	16
Gross unrealized losses	0	(1)
Estimated fair value	810	852
Corporate debt securities - Financial [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	2,957	2,252
Gross unrealized gains	55	53
Gross unrealized losses	(11)	(9)
Estimated fair value	3,001	2,296
Corporate debt securities - Industrial [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	3,131	2,441
Gross unrealized gains	72	71
Gross unrealized losses	(6)	(5)
Estimated fair value	3,197	2,507
Corporate debt securities - Other [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	352	307
Gross unrealized gains	10	10
Gross unrealized losses	(1)	(1)
Estimated fair value	361	316
Mortgage and asset backed securities [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	1,498	841
Gross unrealized gains	4	5
Gross unrealized losses	(7)	(5)
Estimated fair value	1,495	841
Money market mutual funds [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	1,075	3,030
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Estimated fair value	1,075	3,030
Other short-term interest bearing securities [Member]
Fair values of available-for-sale investments by type of security
Amortized cost		147
Gross unrealized gains		0
Gross unrealized losses		0
Estimated fair value		147
Total debt securities [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	15,042	17,057
Gross unrealized gains	175	256
Gross unrealized losses	(50)	(36)
Estimated fair value	15,167	17,277
Equity securities [Member]
Fair values of available-for-sale investments by type of security
Amortized cost	52	50
Gross unrealized gains	0	0
Gross unrealized losses	(4)	(2)
Estimated fair value	$ 48	$ 48

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet38.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-for-sale investments (Details 1) (USD  $) In Millions	Mar. 31, 2011	Dec. 31, 2010
Fair values of available-for-sale investments by contractual maturity
Maturing in one year or less	$ 1,713	$ 4,118
Maturing after one year through three years	7,049	6,736
Maturing after three years through five years	5,367	5,812
Maturing after five years	1,038	611
Total	15,215	17,325
Total debt securities [Member]
Fair values of available-for-sale investments by contractual maturity
Total	15,167	17,277
Equity securities [Member]
Fair values of available-for-sale investments by contractual maturity
Total	$ 48	$ 48

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet39.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-for-sale investments (Details 2) (USD  $) In Millions	Mar. 31, 2011	Dec. 31, 2010	Mar. 31, 2010	Dec. 31, 2009
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$ 1,266	$ 3,287	$ 2,266	$ 2,884
Marketable securities	14,092	14,135
Other assets - noncurrent	48	48
Total including cash	15,406	17,470
Less cash	(191)	(145)
Total	$ 15,215	$ 17,325

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet40.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-for-sale investments (Details Textuals) (USD  $) In Millions	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Available-for-sale securities (Textuals) [Abstract]
Total realized gains	$ 89	$ 21
Total realized losses	$ 8	$ 2

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet41.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Details) (USD  $) In Millions	Mar. 31, 2011	Dec. 31, 2010
Inventories
Raw materials	$ 135	$ 128
Work in process	1,445	1,382
Finished goods	518	512
Inventories	$ 2,098	$ 2,022

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet42.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financing arrangements (Details) (USD  $) In Millions	Mar. 31, 2011	Dec. 31, 2010
Carrying value of long-term borrowings
Convertible notes current	$ 83	$ 2,488
Convertible notes	2,246	2,296
Notes payable	8,578	8,578
Other notes including our zero coupon convertible notes	183	183
Total borrowings	10,907	13,362
Less current portion	(83)	(2,488)
Total non-current debt	10,824	10,874
0.125% convertible notes due 2011 (2011 Convertible notes) [Member]
Carrying value of long-term borrowings
Convertible notes current	0	2,488
Less current portion	0	(2,488)
0.375% convertible notes due 2013 (2013 Convertible notes) [Member]
Carrying value of long-term borrowings
Convertible notes	2,246	2,213
5.85% notes due 2017 (2017 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	1,099	1,099
4.85% notes due 2014 (2014 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	1,000	1,000
5.70% notes due 2019 (2019 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	998	998
6.40% notes due 2039 (2039 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	996	996
6.375% notes due 2037 (2037 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	899	899
3.45% notes due October 2020 (October 2020 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	897	897
5.75% notes due 2040 (2040 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	696	696
4.95% notes due 2041 (2041 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	595	595
6.15% notes due 2018 (2018 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	499	499
6.90% notes due 2038 (2038 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	499	499
4.50% notes due March 2020 (March 2020 Notes) [Member]
Carrying value of long-term borrowings
Notes payable	$ 300	$ 300

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet43.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Financing arrangements (Details Textuals) (USD  $) In Millions, unless otherwise specified	3 Months Ended			3 Months Ended
Mar. 31, 2011	Mar. 31, 2010	Mar. 31, 2011 5.85% notes due 2017 (2017 Notes) [Member]	Dec. 31, 2010 5.85% notes due 2017 (2017 Notes) [Member]	Mar. 31, 2011 0.125% convertible notes due 2011 (2011 Convertible notes) [Member]	Dec. 31, 2010 0.125% convertible notes due 2011 (2011 Convertible notes) [Member]	Mar. 31, 2011 0.375% convertible notes due 2013 (2013 Convertible notes) [Member]	Dec. 31, 2010 0.375% convertible notes due 2013 (2013 Convertible notes) [Member]	Mar. 31, 2011 4.85% notes due 2014 (2014 Notes) [Member]	Dec. 31, 2010 4.85% notes due 2014 (2014 Notes) [Member]	Mar. 31, 2011 5.70% notes due 2019 (2019 Notes) [Member]	Dec. 31, 2010 5.70% notes due 2019 (2019 Notes) [Member]	Mar. 31, 2011 6.15% notes due 2018 (2018 Notes) [Member]	Dec. 31, 2010 6.15% notes due 2018 (2018 Notes) [Member]	Mar. 31, 2011 6.375% notes due 2037 (2037 Notes) [Member]	Dec. 31, 2010 6.375% notes due 2037 (2037 Notes) [Member]	Mar. 31, 2011 4.50% notes due March 2020 (March 2020 Notes) [Member]	Dec. 31, 2010 4.50% notes due March 2020 (March 2020 Notes) [Member]	Mar. 31, 2011 6.90% notes due 2038 (2038 Notes) [Member]	Dec. 31, 2010 6.90% notes due 2038 (2038 Notes) [Member]	Mar. 31, 2011 5.75% notes due 2040 (2040 Notes) [Member]	Dec. 31, 2010 5.75% notes due 2040 (2040 Notes) [Member]	Mar. 31, 2011 6.40% notes due 2039 (2039 Notes) [Member]	Dec. 31, 2010 6.40% notes due 2039 (2039 Notes) [Member]	Mar. 31, 2011 3.45% notes due October 2020 (October 2020 Notes) [Member]	Dec. 31, 2010 3.45% notes due October 2020 (October 2020 Notes) [Member]	Mar. 31, 2011 4.95% notes due 2041 (2041 Notes) [Member]	Dec. 31, 2010 4.95% notes due 2041 (2041 Notes) [Member]
Financing arrangements (Textuals) [Abstract]
Stated contractual interest rate on note			5.85%	5.85%		0.13%	0.38%	0.38%	4.85%	4.85%	5.70%	5.70%	6.15%	6.15%	6.38%	6.38%	4.50%	4.50%	6.90%	6.90%	5.75%	5.75%	6.40%	6.40%	3.45%	3.45%	4.95%	4.95%
Repayment of debt	$ 2,500	$ 0			$ 2,500
Original debt discount					$ 643

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet44.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' equity (Details) (USD  $) In Millions	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Stock repurchase program
Stock repurchases, in dollars	$ 0	$ 1,684
Stock repurchases, in shares	0	29.1

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet45.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' equity (Details Textuals) (USD  $) In Billions	Apr. 30, 2011	Mar. 31, 2011	Dec. 31, 2009
Stockholders' equity (Textuals) [Abstract]
Additional amount authorized by the Board of Directors under a stock repurchase plan	$ 5		$ 5
Amount available for stock repurchases under a Board of Directors approved stock repurchase plan		$ 2.2

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet46.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair value measurement (Details) (USD  $) In Millions	Mar. 31, 2011	Dec. 31, 2010
Assets
Total available-for-sale securities	$ 15,215	$ 17,325
Interest rate swap contracts	217	349
Total assets	15,432	17,674
Liabilities
Interest rate swap contracts	201	103
Total liabilities	391	103
US Treasury securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	3,557	5,080
Other government related debt securities - Obligations of U.S. government agencies and FDIC guaranteed bank debt [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	0	0
Other government related debt securities - Foreign and other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	0	0
Corporate debt securities - Financial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	0	0
Corporate debt securities - Industrial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	0	0
Corporate debt securities - Other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	0	0
Mortgage and asset backed securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	0	0
Money market mutual funds [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	1,075	3,030
Other short-term interest bearing securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities		0
Equity securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total available-for-sale securities	48	48
Quoted prices in active markets for identical assets (Level 1) [Member]
Assets
Total assets	4,680	8,158
Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]
Assets
Foreign currency contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]
Assets
Interest rate swap contracts	0	0
Foreign currency contracts [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Liabilities
Foreign currency contracts	0	0
Interest rate swap contracts [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Liabilities
Interest rate swap contracts	0
Contingent consideration obligations in connection with a business combination [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Liabilities
Contingent consideration in connection with a business combination	0
Quoted prices in active markets for identical assets (Level 1) [Member]
Liabilities
Total liabilities	0	0
US Treasury securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	0	0
Other government related debt securities - Obligations of U.S. government agencies and FDIC guaranteed bank debt [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	1,671	2,208
Other government related debt securities - Foreign and other [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	810	852
Corporate debt securities - Financial [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	3,001	2,296
Corporate debt securities - Industrial [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	3,197	2,507
Corporate debt securities - Other [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	361	316
Mortgage and asset backed securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	1,495	841
Money market mutual funds [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	0	0
Other short-term interest bearing securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities		147
Equity securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets
Total available-for-sale securities	0	0
Significant other observable inputs (Level 2) [Member]
Assets
Total assets	10,752	9,516
Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]
Assets
Foreign currency contracts	57	154
Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]
Assets
Interest rate swap contracts	160	195
Foreign currency contracts [Member] | Significant other observable inputs (Level 2) [Member]
Liabilities
Foreign currency contracts	189	103
Interest rate swap contracts [Member] | Significant other observable inputs (Level 2) [Member]
Liabilities
Interest rate swap contracts	12
Contingent consideration obligations in connection with a business combination [Member] | Significant other observable inputs (Level 2) [Member]
Liabilities
Contingent consideration in connection with a business combination	0
Significant other observable inputs (Level 2) [Member]
Liabilities
Total liabilities	201	103
US Treasury securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Other government related debt securities - Obligations of U.S. government agencies and FDIC guaranteed bank debt [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Other government related debt securities - Foreign and other [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Corporate debt securities - Financial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Corporate debt securities - Industrial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Corporate debt securities - Other [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Mortgage and asset backed securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Money market mutual funds [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Other short-term interest bearing securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities		0
Equity securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets
Total available-for-sale securities	0	0
Significant unobservable inputs (Level 3) [Member]
Assets
Total assets	0	0
Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]
Assets
Foreign currency contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]
Assets
Interest rate swap contracts	0	0
Foreign currency contracts [Member] | Significant unobservable inputs (Level 3) [Member]
Liabilities
Foreign currency contracts	0	0
Interest rate swap contracts [Member] | Significant unobservable inputs (Level 3) [Member]
Liabilities
Interest rate swap contracts	0
Contingent consideration obligations in connection with a business combination [Member] | Significant unobservable inputs (Level 3) [Member]
Liabilities
Contingent consideration in connection with a business combination	190
Significant unobservable inputs (Level 3) [Member]
Liabilities
Total liabilities	190	0
US Treasury securities [Member]
Assets
Total available-for-sale securities	3,557	5,080
Other government related debt securities - Obligations of U.S. government agencies and FDIC guaranteed bank debt [Member]
Assets
Total available-for-sale securities	1,671	2,208
Other government related debt securities - Foreign and other [Member]
Assets
Total available-for-sale securities	810	852
Corporate debt securities - Financial [Member]
Assets
Total available-for-sale securities	3,001	2,296
Corporate debt securities - Industrial [Member]
Assets
Total available-for-sale securities	3,197	2,507
Corporate debt securities - Other [Member]
Assets
Total available-for-sale securities	361	316
Total debt securities [Member]
Assets
Total available-for-sale securities	15,167	17,277
Mortgage and asset backed securities [Member]
Assets
Total available-for-sale securities	1,495	841
Money market mutual funds [Member]
Assets
Total available-for-sale securities	1,075	3,030
Other short-term interest bearing securities [Member]
Assets
Total available-for-sale securities		147
Equity securities [Member]
Assets
Total available-for-sale securities	48	48
Foreign currency contracts [Member]
Assets
Foreign currency contracts	57	154
Liabilities
Foreign currency contracts	189	103
Interest rate swap contracts [Member]
Assets
Interest rate swap contracts	160	195
Liabilities
Interest rate swap contracts	12
Contingent consideration obligations in connection with a business combination [Member]
Liabilities
Contingent consideration in connection with a business combination	$ 190

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet47.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair value measurements (Details 1) (USD  $) In Millions	Mar. 31, 2011	Dec. 31, 2010
Carrying value and estimated fair value of borrowings
Convertible notes current	$ 83	$ 2,488
Convertible notes	2,246	2,296
Notes payable	8,578	8,578
Total notes payable, fair value	11,740	14,547
Other notes including our zero coupon convertible notes	183	183
Other notes including our zero coupon convertible notes, fair value	204	214
Total borrowings	10,907	13,362
0.125% convertible notes due 2011 (2011 Convertible notes) [Member]
Carrying value and estimated fair value of borrowings
Convertible notes current	0	2,488
Convertible notes payable, fair value	0	2,501
0.375% convertible notes due 2013 (2013 Convertible notes) [Member]
Carrying value and estimated fair value of borrowings
Convertible notes	2,246	2,213
Convertible notes payable, fair value	2,480	2,479
5.85% notes due 2017 (2017 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	1,099	1,099
Total notes payable, fair value	1,245	1,280
4.85% notes due 2014 (2014 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	1,000	1,000
Total notes payable, fair value	1,094	1,101
5.70% notes due 2019 (2019 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	998	998
Total notes payable, fair value	1,107	1,139
6.40% notes due 2039 (2039 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	996	996
Total notes payable, fair value	1,089	1,149
6.375% notes due 2037 (2037 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	899	899
Total notes payable, fair value	974	1,027
3.45% notes due October 2020 (October 2020 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	897	897
Total notes payable, fair value	836	857
5.75% notes due 2040 (2040 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	696	696
Total notes payable, fair value	699	734
4.95% notes due 2041 (2041 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	595	595
Total notes payable, fair value	546	564
6.15% notes due 2018 (2018 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	499	499
Total notes payable, fair value	568	584
6.90% notes due 2038 (2038 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	499	499
Total notes payable, fair value	591	607
4.50% notes due March 2020 (March 2020 Notes) [Member]
Carrying value and estimated fair value of borrowings
Notes payable	300	300
Total notes payable, fair value	$ 307	$ 311

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet48.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair value measurements (Details Textuals) (USD  $)	Mar. 31, 2011	Dec. 31, 2010
Fair Value Measurement (Textuals) [Abstract]
Interest rate swap contracts - fair value hedge - notional amounts	$ 3,600,000,000	$ 3,600,000,000
Foreign currency forward contracts [Member]
Fair Value Measurement (Textuals) [Abstract]
Foreign currency open contracts - cash flow hedges - notional amounts	3,400,000,000	3,200,000,000
Foreign currency open contracts - not designated as hedges - notional amounts	788,000,000	670,000,000
Foreign currency option contracts [Member]
Fair Value Measurement (Textuals) [Abstract]
Foreign currency open contracts - cash flow hedges - notional amounts	$ 300,000,000	$ 398,000,000

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet49.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative instruments (Details) (Derivatives in cash flow hedging relationships [Member], USD  $) In Millions	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Effective portion of the unrealized gain/(loss) recognized in Other Comprehensive Income for our cash flow hedge contracts
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$ (197)	$ 175
Forward interest rate contracts [Member]
Effective portion of the unrealized gain/(loss) recognized in Other Comprehensive Income for our cash flow hedge contracts
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	0	0
Foreign currency contracts [Member]
Effective portion of the unrealized gain/(loss) recognized in Other Comprehensive Income for our cash flow hedge contracts
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$ (197)	$ 175

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet50.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative instruments (Details 1) (USD  $) In Millions	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our cash flow hedge contracts
Total	$ (8)	$ (6)
Forward interest rate contracts [Member]
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our cash flow hedge contracts
The amount of gain (loss) recognized in interest expense, net	0	0
Foreign currency contracts [Member]
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our cash flow hedge contracts
The amount of gain (loss) recognized in product sales	$ (8)	$ (6)

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet51.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative instruments (Details 2) (Foreign currency contracts [Member], Interest and other income, net [Member], USD  $) In Millions	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010
Location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for the derivative instruments not designated as hedging instruments
Derivatives not designated as hedging instruments	$ (51)	$ 23

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet52.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative instruments (Details 3) (USD  $) In Millions	Mar. 31, 2011	Dec. 31, 2010
Assets
Total derivatives designated as hedging instruments	$ 217	$ 349
Total derivatives not designated as hedging instruments	0	0
Total derivatives	217	349
Liabilities
Total derivatives designated as hedging instruments	201	103
Total derivatives not designated as hedging instruments	0	0
Total derivatives	201	103
Interest rate swap contracts [Member] | Accrued liabilities/other noncurrent liabilities [Member]
Liabilities
Total derivatives designated as hedging instruments	12	0
Interest rate swap contracts [Member] | Other current assets/other non-current assets [Member]
Assets
Total derivatives designated as hedging instruments	160	195
Foreign currency contracts [Member] | Accrued liabilities/other noncurrent liabilities [Member]
Liabilities
Total derivatives designated as hedging instruments	189	103
Foreign currency contracts [Member] | Accrued Liabilities[ Member]
Liabilities
Total derivatives not designated as hedging instruments	0	0
Foreign currency contracts [Member] | Other current assets/other non-current assets [Member]
Assets
Total derivatives designated as hedging instruments	57	154
Foreign currency contracts [Member] | Other Current Assets [Member]
Assets
Total derivatives not designated as hedging instruments	$ 0	$ 0

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet53.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative instruments (Details Textuals) (USD  $)	3 Months Ended
Mar. 31, 2011	Mar. 31, 2010	Dec. 31, 2010
Derivative instruments (Textuals) [Abstract]
Length of time hedged in foreign currency cash flow hedge	Approximately 3 years
Ineffective portions of cash flow hedging instruments (approximately)	$ (1,000,000)	$ 1,000,000
Interest rate swap contracts - fair value hedge - notional amounts	3,600,000,000		3,600,000,000
Unrealized gain (loss) on the hedged debt	47,000,000	(17,000,000)
Offsetting unrealized gain (loss) on related interest rate swaps	(47,000,000)	17,000,000
Derivative lower range variable interest rate	LIBOR plus 0.3%
Derivative higher range variable interest rate	LIBOR plus 2.6%
Foreign currency forward contracts [Member]
Derivative instruments (Textuals) [Abstract]
Foreign currency open contracts - cash flow hedges - notional amounts	3,400,000,000		3,200,000,000
Foreign currency open contracts - not designated as hedges - notional amounts	788,000,000		670,000,000
Foreign currency option contracts [Member]
Derivative instruments (Textuals) [Abstract]
Foreign currency open contracts - cash flow hedges - notional amounts	300,000,000		398,000,000
Foreign currency forward and option contracts [Member]
Derivative instruments (Textuals) [Abstract]
Amounts expected to be reclassified from accumulated other comprehensive income into income over the next 12 months - gain (loss)	(104,000,000)
Forward interest rate contracts [Member]
Derivative instruments (Textuals) [Abstract]
Amounts expected to be reclassified from accumulated other comprehensive income into income over the next 12 months - gain (loss)	$ (1,000,000)

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/Sheet54.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Subsequent events (Details) (Bergamo [Member], USD  $) In Millions, unless otherwise specified	1 Months Ended
Apr. 30, 2011
Subsequent events (Textuals) [Abstract]
Number of staff in acquired company	400
Cash payment for acquisition	$ 215

------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b Content-Location: file:///C:/5e121c23_0040_4890_92e5_367acd97a52b/Worksheets/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii" ------=_NextPart_5e121c23_0040_4890_92e5_367acd97a52b--